Kazakhstan intends to expand its pharmaceutical export potential. Updated rules for concluding long-term contracts will come into force next year, according to the ministry. The new regulations are aimed at localizing pharmaceutical production, developing technology transfer, and providing comprehensive support to domestic manufacturers. More than 200 Kazakh producers are currently registered in the country. Over the first ten months of this year, the output of local enterprises increased by 12 percent, exceeding 156 billion tenge. It is also proposed to exempt imported raw materials used in pharmaceutical production from value-added tax (VAT). To ensure the quality of domestically produced medicines, a goal has been set to bring the national regulatory system to the maturity level 3 (ML3). Kazakhstan will become the first country in the post-Soviet space to reach this level and to be recognized as a state with a stringent regulatory framework.
«As part of digitalization efforts, in 2024 the Ministry implemented a
system for labeling and traceability of medicinal products. Today, Kazakhstan
is the only country in Central Asia to have launched the full cycle of this
process. As part of the labeling, the process of planning medicine procurement
volumes was digitalized, enabling
more accurate demand forecasting. In addition, to ensure the prompt release of
products to the market, the registration procedure was simplified and
registration timeframes were cut by half,» said Kazakh Minister of Health Akmaral Alnazarova.
Related Articles
